The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...

Longevity investment went from $3.8bn in 2023 to $8.5bn in 2024 (albeit in the context of a broader biotech market recovery).

Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological diseases – a mission that will be helped by adding ...

Daiichi Sankyo has reported its delayed financial results, saying that high spending on third-party manufacturing and a lower-than-expected take-up of its antibody-drug conjugates for cancer led to a ...

The company behind a search agent to assist clinical decision-making – OpenEvidence – has raised an impressive $210 million in a second-round financing that will support the launch of a tool that can ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and validate drug targets and train AI models used in drug discovery. The first ...

Cidara Therapeutics is celebrating a major injection of funding from the US government that will be used to support the development of its experimental preventive therapy for influenza. The sizeable ...

Top priorities at the FDA in the coming years will include shorter review timelines for drug development, embracing the use of artificial intelligence and big data, and speeding up approvals for ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

Danish GLP-1 giant Novo Nordisk announced a restructuring effort today that will cut 9,000 jobs, a little over 11% of its global workforce. The cut comes a little over a month after the start of new ...